Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Breast Neoplasms 379Neoplasms 336Carcinoma, Non-Small-Cell Lung 297Prostatic Neoplasms 250Colorectal Neoplasms 223Lung Neoplasms 195Multiple Myeloma 155Ovarian Neoplasms 142Pancreatic Neoplasms 140Neoplasm Metastasis 132Leukemia, Myeloid, Acute 129Melanoma 112Squamous Cell Carcinoma of Head and Neck 96Lymphoma 89Carcinoma, Renal Cell 89Stomach Neoplasms 87Recurrence 87Lymphoma, Non-Hodgkin 86Endometrial Neoplasms 85Brain Neoplasms 83Carcinoma, Hepatocellular 82Precursor Cell Lymphoblastic Leukemia-Lymphoma 81Head and Neck Neoplasms 73Glioma 73Glioblastoma 73Uterine Cervical Neoplasms 71Sarcoma 69Urinary Bladder Neoplasms 67Hematologic Neoplasms 66Leukemia, Lymphocytic, Chronic, B-Cell 65

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Differentiated Thyroid Cancer (DTC) × 30 days × Clear all
NCT04940052 2026-06-04

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Novartis

Phase 3 Active not recruiting
153 enrolled 15 charts
EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡